Glipizide/Glucotrol XL Oral Tab ER: 2.5mg, 5mg, 10mg. Disulfiram-like reaction with alcohol (rare). Impaired GI function or GI narrowing (XL); avoid.
INTRODUCTION — The prevalence of type 2 diabetes continues to increase steadily as more people live longer and grow heavier. Increased risk of cardiovascular mortality. 22 Nov. 2019. Pregnancy: discontinue at least 2 weeks before expected delivery. Monitor for 1–2 weeks if transferring from long-acting sulfonylureas.Hypoglycemia, tremor, asthenia, diarrhea, flatulence, allergic skin reactions, photosensitivity, blood dyscrasias, hyponatremia, dizziness, drowsiness, headache; rare: cholestatic jaundice, hepatic porphyria.Copyright © 2020 Haymarket Media, Inc. All Rights Reserved Select one or more newsletters to continue. Applies to: SIADH, Hyponatremia, DehydrationTreatment with sulfonylureas may cause hyponatremia, in patients who are on other medications or have medical conditions known to cause hyponatremia or increase release of antidiuretic hormone. Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study. Hypoglycemia, if it occurs during treatment, may be prolonged in these patients because of slowed metabolism and/or excretion of the drugs.Moderate Potential Hazard, Moderate plausibility. Adjunct to diet and exercise in type 2 diabetes mellitus. Elderly, debilitated, uncompensated strenuous exercise, malnourished or deficient caloric intake, adrenal or pituitary insufficiency, or alcohol intoxication: increased risk of hypoglycemia. Major Potential Hazard, Moderate plausibility. Usual range: 5–10mg once daily; max 20mg daily. The syndrome of inappropriate antidiuretic hormone (SIADH) secretion has been reported with certain sulfonylureas and these drugs may augment the peripheral (antidiuretic) action of ADH and/or increase release of ADH. There have been postmarketing reports of hemolytic anemia in patients receiving these drugs who did not have known G6PD deficiency.Moderate Potential Hazard, Moderate plausibility. Nursing mothers: monitor infants for hypoglycemia.May be potentiated by concomitant oral miconazole, fluconazole, or drugs affecting glucose metabolism (eg, ACEIs, ARBs, NSAIDs, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, MAOIs, quinolones); monitor closely for hypoglycemia with co-administration and for worsening glycemic control upon withdrawal (see full labeling). Older adults (>65 years) with diabetes are at risk of developing a similar spectrum of microvascular complications as their younger counterparts with diabetes, albeit probably at lower absolute risk if they develop their diabetes later in life, which will limit duration. Applies to: G-6-PD DeficiencySulfonylureas can cause hemolytic anemia in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency. Reference for “Relationship between Type 2 Diabetes and Atherosclerotic Cardiovascular Disease”: Gan, Wei et al. Data Source and Processing. Data were obtained from the publicly accessible FAERS database (first quarter of 2004 through fourth quarter of 2010), which is a computerized information system where healthcare professionals and consumers send adverse event reports voluntarily through the MedWatch program [].The system includes all serious and unlabelled spontaneous reports from the USA and non … Glucotrol and Glucotrol XL, like all oral antidiabetic drugs, can cause low blood sugar. Low risk of hypoglycemia Gastrointestinal side effects First line treatment 1-1.5% Metformin ... to increased risk of hypoglycemia Glipizide Glucotrol XL® 5mg daily 5 to 10mg daily Up to 20mg daily No dosing adjustments required ... heart failure patients, black box warning. Neonates. Available for Android and iOS devices.
INTRODUCTION — The prevalence of type 2 diabetes continues to increase steadily as more people live longer and grow heavier. Increased risk of cardiovascular mortality. 22 Nov. 2019. Pregnancy: discontinue at least 2 weeks before expected delivery. Monitor for 1–2 weeks if transferring from long-acting sulfonylureas.Hypoglycemia, tremor, asthenia, diarrhea, flatulence, allergic skin reactions, photosensitivity, blood dyscrasias, hyponatremia, dizziness, drowsiness, headache; rare: cholestatic jaundice, hepatic porphyria.Copyright © 2020 Haymarket Media, Inc. All Rights Reserved Select one or more newsletters to continue. Applies to: SIADH, Hyponatremia, DehydrationTreatment with sulfonylureas may cause hyponatremia, in patients who are on other medications or have medical conditions known to cause hyponatremia or increase release of antidiuretic hormone. Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study. Hypoglycemia, if it occurs during treatment, may be prolonged in these patients because of slowed metabolism and/or excretion of the drugs.Moderate Potential Hazard, Moderate plausibility. Adjunct to diet and exercise in type 2 diabetes mellitus. Elderly, debilitated, uncompensated strenuous exercise, malnourished or deficient caloric intake, adrenal or pituitary insufficiency, or alcohol intoxication: increased risk of hypoglycemia. Major Potential Hazard, Moderate plausibility. Usual range: 5–10mg once daily; max 20mg daily. The syndrome of inappropriate antidiuretic hormone (SIADH) secretion has been reported with certain sulfonylureas and these drugs may augment the peripheral (antidiuretic) action of ADH and/or increase release of ADH. There have been postmarketing reports of hemolytic anemia in patients receiving these drugs who did not have known G6PD deficiency.Moderate Potential Hazard, Moderate plausibility. Nursing mothers: monitor infants for hypoglycemia.May be potentiated by concomitant oral miconazole, fluconazole, or drugs affecting glucose metabolism (eg, ACEIs, ARBs, NSAIDs, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, MAOIs, quinolones); monitor closely for hypoglycemia with co-administration and for worsening glycemic control upon withdrawal (see full labeling). Older adults (>65 years) with diabetes are at risk of developing a similar spectrum of microvascular complications as their younger counterparts with diabetes, albeit probably at lower absolute risk if they develop their diabetes later in life, which will limit duration. Applies to: G-6-PD DeficiencySulfonylureas can cause hemolytic anemia in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency. Reference for “Relationship between Type 2 Diabetes and Atherosclerotic Cardiovascular Disease”: Gan, Wei et al. Data Source and Processing. Data were obtained from the publicly accessible FAERS database (first quarter of 2004 through fourth quarter of 2010), which is a computerized information system where healthcare professionals and consumers send adverse event reports voluntarily through the MedWatch program [].The system includes all serious and unlabelled spontaneous reports from the USA and non … Glucotrol and Glucotrol XL, like all oral antidiabetic drugs, can cause low blood sugar. Low risk of hypoglycemia Gastrointestinal side effects First line treatment 1-1.5% Metformin ... to increased risk of hypoglycemia Glipizide Glucotrol XL® 5mg daily 5 to 10mg daily Up to 20mg daily No dosing adjustments required ... heart failure patients, black box warning. Neonates. Available for Android and iOS devices.